Publikationen in Zusammenarbeit mit Forschern von New York University School of Medicine (17)

2013

  1. Assessing remission in rheumatoid arthritis on the basis of patient reported outcomes: Advantages of using RAPID3/MDHAQ in routine care

    Bulletin of the Hospital for Joint Diseases, Vol. 72, Núm. 2, pp. 136-141

  2. Documenting the value of care for rheumatoid arthritis, analogous to hypertension, diabetes, and hyperlipidemia: Is control of individual patient self-report measures of global estimate and physical function more valuable than laboratory tests, radiographs, indices, or remission criteria?

    Journal of Rheumatology

  3. Efficacy and safety of methotrexate in combination with other Non-Biologic diseasemodifying antirheumatic drugs (DMARDs) in treatment of rheumatoid arthritis

    Bulletin of the Hospital for Joint Diseases, Vol. 71, pp. S20-S28

  4. Evidence that the strategy is more important than the agent to treat rheumatoid arthritis: Data from clinical trials of combinations of non-biologic dmards, with Protocol-Driven intensification of therapy for tight control or Treat-To-Target

    Bulletin of the Hospital for Joint Diseases, Vol. 71, pp. S33-S40

  5. GUEPARD treat-to-target strategy is significantly more efficacious than ESPOIR routine care in early rheumatoid arthritis according to patient-reported outcomes and physician global estimate

    Rheumatology (United Kingdom), Vol. 52, Núm. 10, pp. 1890-1897

  6. RHEUMDOC: A one-page RHEUMatology DOCtor form with four physician global estimates for overall status, inflammation, damage, and symptoms based on neither inflammation nor damage

    Bulletin of the Hospital for Joint Diseases, Vol. 72, Núm. 2, pp. 142-147

  7. Update on methotrexate as the anchor drug for rheumatoid arthritis

    Bulletin of the Hospital for Joint Diseases, Vol. 71, pp. S9-S19